We are living in a golden age of biopharmaceutical innovation. Yet, too often, patients face barriers between them and the appropriate treatment they need across various cost-shifting programs. Payers often focus on drugs to manage healthcare costs, implementing programs such as copay accumulators, maximizers, and alternative funding programs. However, research shows that these are negatively impacting patient access and health. During this session, panelists will answer questions as to why the prevalence of high deductibles and patient cost-sharing is increasing, how high cost-sharing can negatively affect patient adherence, and what policies and/or regulations should be considered to protect patient access.